Tuesday, October 13, 2026

Virgin Galactic Already 4% Up, Almost Four Hours Before The NYSE Open

Virgin Galactic Already 4% Up, Almost Four Hours Before The NYSE Open

(VIANEWS) - The NYSE opens in less than four hours and Virgin Galactic's pre-market value is already 4.73% up.

The last session, NYSE finished with Virgin Galactic (SPCE) sliding 16.54% to $3.38. NYSE jumped 0.69% to $15,078.69, following the last session's upward trend on what was a somewhat bullish trend exchanging session.

About Virgin Galactic

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.61.

Growth Estimates Quarters

The company's growth estimates for the present quarter is a negative 20.9% and positive 12.7% for the next.

Volume

Today's last reported volume for Virgin Galactic is 29143687 which is 196.63% above its average volume of 9824940.

Sales Growth

Virgin Galactic's sales growth is 625.5% for the current quarter and 368.1% for the next.

More news about Virgin Galactic (SPCE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com